Events

One Nucleus | Genesis 2020 w/ Alix Lacoste

Hope, Hype and Reality of AI in Drug Discovery

Join BenevolentAI’s VP Applied Sciences at One Nucleus Genesis where she will be speaking on 'Hope, Hype and Reality of AI in Drug Discovery’.

Format

10 Minute Presentation: Introduction to what Pharma needs from AI with Vishal Sahni

10 Minute Presentation: Approaching AI in Drug Discovery with Alix Lacoste

Close: Q&A discussion on the potential and challenges of applying AI in drug discovery with:
Vishal Sahni | Director Discovery Research, MSD
Alix Lacoste | VP Applied Sciences, BenevolentAI
Steve Crossan | VP AI and ML at GSK
Rabia Khan


Alix Lacoste

VP Data Science, New York Site Lead

Alix has significant experience using data science and machine learning to advance biomedical discoveries. She holds a PhD in Molecular and Cellular Biology from Harvard University. Previously at IBM Watson Health, Alix led computational research projects in target identification and drug repurposing, most notably for Parkinson’s disease and amyotrophic lateral sclerosis, in collaboration with academic and pharma partners. At BenevolentAI, Alix connects AI and Drug Discovery groups to continuously improve the hypothesis generation pipeline.

More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022